CND Life Sciences
Scottsdale
About CND Life Sciences
CND Life Sciences provides a diagnostic test and associated services that enable clinicians to detect, visualize, and quantify the phosphorylated form of alpha-synuclein in cutaneous nerve fibers. Its core offering’the Syn-One Test- leverages a minimally invasive skin-biopsy procedure to assist in the diagnostic evaluation of synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. The company also offers laboratory services that apply immunofluorescence and intraepidermal nerve fibre density assessment to support clinical decision-making in neurodegenerative and autonomic disorders. In addition, it collaborates with biopharmaceutical organisations to support clinical trials through biomarker services and longitudinal assessment of nerve-based pathology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $46.6M
- Funding stage: Early Stage Venture
- Last round: Grant (Oct 2025)
- Website: cndlifesciences.com
- Phone: 480-569-2900
Industries & Categories
Biotechnology, Health Diagnostics, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/cnd-life-sciences-6655 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.